FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 349:1027-1035 September 11, 2003 Number 11 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Perspective by Cannon, R. O. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Microvascular dysfunction, reflected by an inadequate increase in myocardial blood flow in response to dipyridamole infusion, is a recognized feature of hypertrophic cardiomyopathy. Its long-term effect on the prognosis is unknown. We prospectively evaluated a cohort of patients with hypertrophic cardiomyopathy after they had undergone quantitative assessment of myocardial blood flow by positron-emission tomography (PET).

Methods Fifty-one patients (New York Heart Association class I or II) were followed for a mean (±SD) of 8.1±2.1 years after PET. Twelve subjects with atypical chest pain served as controls. Measurement of flow was performed at base line and after the infusion of the coronary vasodilator dipyridamole, with the use of nitrogen-13–labeled ammonia. Patients were then divided into three equal groups with increasing values of myocardial blood flow.

Results The response of myocardial blood flow to dipyridamole was severely blunted in the patients, as compared with the controls (1.50±0.69 vs. 2.71±0.94 ml per minute per gram of tissue, P<0.001). Sixteen patients (31 percent) had an unfavorable outcome (death from cardiovascular causes, progression to New York Heart Association class III or IV, or sustained ventricular arrhythmias requiring the implantation of a cardioverter–defibrillator) 2.2 to 9.1 years after PET. Reduced blood flow in response to dipyridamole was strongly associated with an unfavorable outcome. Multivariate analysis showed that among patients in the lowest of the three flow groups the age-adjusted relative hazard of death from cardiovascular causes was 9.6 (P=0.02) and the relative hazard of an unfavorable outcome (a combined end point) was 20.1 (P=0.003), as compared with patients in the two other flow groups. Specifically, all four patients who died from heart failure and three of five who died suddenly were in this subgroup.

Conclusions In patients with hypertrophic cardiomyopathy, the degree of microvascular dysfunction is a strong, independent predictor of clinical deterioration and death. Severe microvascular dysfunction is often present in patients with mild or no symptoms and may precede clinical deterioration by years.

Source Information

From the Regional Referral Center for Myocardial Diseases, Azienda Ospedaliera Careggi, Florence (F.C., I.O., R.G.); the Cardiology Unit, Ospedale di Lucca, Lucca (R.L.); the Cardiology Unit, Ospedale di Pescia, Pescia (G.C.); the Consiglio Nazionale delle Ricerche Institute of Clinical Physiology, Pisa (P.G.C.) — all in Italy; and the Medical Research Centre, Hammersmith Hospital, Imperial College, London (P.G.C.).

Address reprint requests to Dr. Cecchi at Via Jacopo Nardi 30, 50132 Florence, Italy, or at franco.cecchi{at}asf.toscana.it.

Full Text of this Article

This article has been cited by other articles:

• Turkmen, K., Oflaz, H., Uslu, B., Cimen, A. O., Elitok, A., Kasikcioglu, E., Alisir, S., Tufan, F., Namli, S., Uysal, M., Ecder, T. (2008). Coronary Flow Velocity Reserve and Carotid Intima Media Thickness in Patients with Autosomal Dominant Polycystic Kidney Disease: From Impaired Tubules to Impaired Carotid and Coronary Arteries. CJASN 3: 986-991 [Abstract] [Full Text]  
• Sotgia, B., Sciagra, R., Olivotto, I., Casolo, G., Rega, L., Betti, I., Pupi, A., Camici, P. G., Cecchi, F. (2008). Spatial Relationship Between Coronary Microvascular Dysfunction and Delayed Contrast Enhancement in Patients with Hypertrophic Cardiomyopathy. JNM 49: 1090-1096 [Abstract] [Full Text]  
• Dimitrow, P P, Undas, A, Bober, M, Tracz, W, Dubiel, J S (2008). Obstructive hypertrophic cardiomyopathy is associated with enhanced thrombin generation and platelet activation. Heart 94: e21-e21 [Abstract] [Full Text]  
• Knuuti, J, Bengel, F M (2008). Positron emission tomography and molecular imaging. Heart 94: 360-367 [Abstract] [Full Text]  
• Knaapen, P., Germans, T., Camici, P. G., Rimoldi, O. E., ten Cate, F. J., ten Berg, J. M., Dijkmans, P. A., Boellaard, R., van Dockum, W. G., Gotte, M. J. W., Twisk, J. W. R., van Rossum, A. C., Lammertsma, A. A., Visser, F. C. (2008). Determinants of coronary microvascular dysfunction in symptomatic hypertrophic cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 294: H986-H993 [Abstract] [Full Text]  
• Soliman, O. I I, Knaapen, P., Geleijnse, M. L, Dijkmans, P. A, Anwar, A. M, Nemes, A., Michels, M., Vletter, W. B, Lammertsma, A. A, ten Cate, F. J (2007). Assessment of intravascular and extravascular mechanisms of myocardial perfusion abnormalities in obstructive hypertrophic cardiomyopathy by myocardial contrast echocardiography. Heart 93: 1204-1212 [Abstract] [Full Text]  
• Cheung, N., Bluemke, D. A., Klein, R., Sharrett, A. R., Islam, F.M. A., Cotch, M. F., Klein, B. E.K., Criqui, M. H., Wong, T. Y. (2007). Retinal Arteriolar Narrowing and Left Ventricular Remodeling: The Multi-Ethnic Study of Atherosclerosis. J Am Coll Cardiol 50: 48-55 [Abstract] [Full Text]  
• Petersen, S. E., Jerosch-Herold, M., Hudsmith, L. E., Robson, M. D., Francis, J. M., Doll, H. A., Selvanayagam, J. B., Neubauer, S., Watkins, H. (2007). Evidence for Microvascular Dysfunction in Hypertrophic Cardiomyopathy: New Insights From Multiparametric Magnetic Resonance Imaging. Circulation 115: 2418-2425 [Abstract] [Full Text]  
• Zhu, X.-Y., Daghini, E., Chade, A. R., Napoli, C., Ritman, E. L., Lerman, A., Lerman, L. O. (2007). Simvastatin Prevents Coronary Microvascular Remodeling in Renovascular Hypertensive Pigs. J. Am. Soc. Nephrol. 18: 1209-1217 [Abstract] [Full Text]  
• Bayes-Genis, A. (2007). Hypertrophy and inflammation: too much for one heart. Eur Heart J 0: ehm008v1-3 [Full Text]  
• Frustaci, A., Verardo, R., Caldarulo, M., Acconcia, M. C., Russo, M. A., Chimenti, C. (2007). Myocarditis in hypertrophic cardiomyopathy patients presenting acute clinical deterioration. Eur Heart J 28: 733-740 [Abstract] [Full Text]  
• Camici, P. G., Crea, F. (2007). Coronary Microvascular Dysfunction. NEJM 356: 830-840 [Full Text]  
• Graf, S., Khorsand, A., Gwechenberger, M., Novotny, C., Kletter, K., Sochor, H., Pirich, C., Maurer, G., Porenta, G., Zehetgruber, M. (2007). Typical Chest Pain and Normal Coronary Angiogram: Cardiac Risk Factor Analysis Versus PET for Detection of Microvascular Disease. JNM 48: 175-181 [Abstract] [Full Text]  
• Bax, J J, Beanlands, R S, Klocke, F J, Knuuti, J, Lammertsma, A A, Schaefers, M A, Schelbert, H R, Von Schulthess, G K, Shaw, L J, Yang, G Z, Camici, P G (2007). Diagnostic and clinical perspectives of fusion imaging in cardiology: is the total greater than the sum of its parts?. Heart 93: 16-22 [Abstract] [Full Text]  
• Nagueh, S. F., Mahmarian, J. J. (2006). Noninvasive Cardiac Imaging in Patients With Hypertrophic Cardiomyopathy. J Am Coll Cardiol 48: 2410-2422 [Abstract] [Full Text]  
• Westerhof, N., Boer, C., Lamberts, R. R., Sipkema, P. (2006). Cross-talk between cardiac muscle and coronary vasculature.. Physiol. Rev. 86: 1263-1308 [Abstract] [Full Text]  
• Harris, K. M., Spirito, P., Maron, M. S., Zenovich, A. G., Formisano, F., Lesser, J. R., Mackey-Bojack, S., Manning, W. J., Udelson, J. E., Maron, B. J. (2006). Prevalence, Clinical Profile, and Significance of Left Ventricular Remodeling in the End-Stage Phase of Hypertrophic Cardiomyopathy. Circulation 114: 216-225 [Abstract] [Full Text]  
• D'Andrea, A., Caso, P., Severino, S., Cuomo, S., Capozzi, G., Calabro, P., Cice, G., Ascione, L., Scherillo, M., Calabro, R. (2006). Prognostic value of intra-left ventricular electromechanical asynchrony in patients with hypertrophic cardiomyopathy. Eur Heart J 27: 1311-1318 [Abstract] [Full Text]  
• Rigo, F., Gherardi, S., Galderisi, M., Pratali, L., Cortigiani, L., Sicari, R., Picano, E. (2006). The prognostic impact of coronary flow-reserve assessed by Doppler echocardiography in non-ischaemic dilated cardiomyopathy. Eur Heart J 27: 1319-1323 [Abstract] [Full Text]  
• Spirito, P., Autore, C. (2006). Management of hypertrophic cardiomyopathy.. BMJ 332: 1251-1255 [Full Text]  
• Olivotto, I., Cecchi, F., Gistri, R., Lorenzoni, R., Chiriatti, G., Girolami, F., Torricelli, F., Camici, P. G. (2006). Relevance of Coronary Microvascular Flow Impairment to Long-Term Remodeling and Systolic Dysfunction in Hypertrophic Cardiomyopathy. J Am Coll Cardiol 47: 1043-1048 [Abstract] [Full Text]  
• D'Andrea, A, Caso, P, Cuomo, S, Salerno, G, Scarafile, R, Mita, C, De Corato, G, Sarubbi, B, Scherillo, M, Calabro, R, Citro, R (2006). Prognostic value of intra-left ventricular electromechanical asynchrony in patients with mild hypertrophic cardiomyopathy compared with power athletes * Commentary.. Br. J. Sports. Med. 40: 244-250 [Abstract] [Full Text]  
• Cunningham, K S, Veinot, J P, Butany, J (2006). An approach to endomyocardial biopsy interpretation. J. Clin. Pathol. 59: 121-129 [Abstract] [Full Text]  
• Sato, A., Tarnow, L., Nielsen, F.S., Knudsen, E., Parving, H.-H. (2005). Left ventricular hypertrophy in normoalbuminuric type 2 diabetic patients not taking antihypertensive treatment. QJM 98: 879-884 [Abstract] [Full Text]  
• Ommen, S. R. (2005). There Is Much More to the Recipe Than Just Outflow Obstruction. J Am Coll Cardiol 46: 1551-1552 [Full Text]  
• Dessy, C., Saliez, J., Ghisdal, P., Daneau, G., Lobysheva, I. I., Frerart, F., Belge, C., Jnaoui, K., Noirhomme, P., Feron, O., Balligand, J.-L. (2005). Endothelial {beta}3-Adrenoreceptors Mediate Nitric Oxide-Dependent Vasorelaxation of Coronary Microvessels in Response to the Third-Generation {beta}-Blocker Nebivolol. Circulation 112: 1198-1205 [Abstract] [Full Text]  
• Olivotto, I., Maron, M. S., Adabag, A. S., Casey, S. A., Vargiu, D., Link, M. S., Udelson, J. E., Cecchi, F., Maron, B. J. (2005). Gender-Related Differences in the Clinical Presentation and Outcome of Hypertrophic Cardiomyopathy. J Am Coll Cardiol 46: 480-487 [Abstract] [Full Text]  
• Knaapen, P., van Dockum, W. G., Bondarenko, O., Kok, W. E.M., Gotte, M. J.W., Boellaard, R., Beek, A. M., Visser, C. A., van Rossum, A. C., Lammertsma, A. A., Visser, F. C. (2005). Delayed Contrast Enhancement and Perfusable Tissue Index in Hypertrophic Cardiomyopathy: Comparison Between Cardiac MRI and PET. JNM 46: 923-929 [Abstract] [Full Text]  
• Woo, A., Williams, W. G., Choi, R., Wigle, E. D., Rozenblyum, E., Fedwick, K., Siu, S., Ralph-Edwards, A., Rakowski, H. (2005). Clinical and Echocardiographic Determinants of Long-Term Survival After Surgical Myectomy in Obstructive Hypertrophic Cardiomyopathy. Circulation 111: 2033-2041 [Abstract] [Full Text]  
• Wong, T. Y., Rosamond, W., Chang, P. P., Couper, D. J., Sharrett, A. R., Hubbard, L. D., Folsom, A. R., Klein, R. (2005). Retinopathy and Risk of Congestive Heart Failure. JAMA 293: 63-69 [Abstract] [Full Text]  
• Kaufmann, P. A., Camici, P. G. (2005). Myocardial Blood Flow Measurement by PET: Technical Aspects and Clinical Applications. JNM 46: 75-88 [Full Text]  
• (2003). Microvascular Dysfunction and HCM Prognosis. Journal Watch Cardiology 2003: 4-4 [Full Text]